Meeting
2018 ASCO Annual Meeting
In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.
Authors
Hatem Hussein Soliman
Moffitt Cancer Center, Tampa, FL
Hatem Hussein Soliman , Mark E. Robson , Susanne Wagner , Darl D Flake II, Lee Steven Schwartzberg , Priyanka Sharma , Anthony Martin Magliocco , Ralf Kronenwett , Johnathan M. Lancaster , Jerry S Lanchbury , Alexander Gutin , William John Gradishar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 539)
DOI
10.1200/JCO.2018.36.15_suppl.539
Abstract #
539
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2018 ASCO Annual Meeting
Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.
First Author: Nishant Verma
Poster
2018 ASCO Annual Meeting
Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.
First Author: Philip Daniel Poorvu